NeoStem, Inc. , an emerging leader in the fast growing cell therapy market, today announced that, on March 6, 2013, it received approval to continue its PreSERVE AMI Phase 2 clinical trial following its second interim data and safety review by the Data Safety Monitoring Board .
http://www.pressreleasepoint.com/neostem-reports-second-data-safety-monitoring-board-review-continue-preserve-ami-phase-2-trial-plann
http://www.pressreleasepoint.com/neostem-reports-second-data-safety-monitoring-board-review-continue-preserve-ami-phase-2-trial-plann
No comments:
Post a Comment